Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 08:00 ET | Source: Belite Bio, Inc

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjectsA trend for stabilized or improved visual acuity was observedObserved adverse events were...
May 03, 2022 16:30 ET | Source: Belite Bio, Inc

Belite Bio Announces Closing of $36 Million Initial Public Offering

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable...
May 03, 2022 06:50 ET | Source: Belite Bio, Inc

Belite Bio Receives FDA Fast Track Designation For LBS-008

LBS-008 (aka Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1)There are currently no approved treatments for STGD1A 2-year Phase 2 trial in...
April 28, 2022 18:59 ET | Source: Belite Bio, Inc

Belite Bio Announces Pricing of $36 Million Initial Public Offering

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable...